1e
19
1
49
2
2
18
1b
1d
18
34
69
1d
2 29
1d
25
Amy S. Clark, MD, MSCE
78
69
Jill and Alan Miller Associate Professor in Breast Cancer Excellence
28
6d
3
5f
Attending, Hospital of the University of Pennsylvania
a0
Physician Lead, Breast Cancer Clinical Research Unit, University of Pennsylvania, Abramson Cancer Center
95
Medical Director, Clinical Research Unit , University of Pennsylvania, Abramson Cancer Center
11
Department: Medicine
4
1
b
1d
46
Contact information
4e
4
3
3
3
2
4
b
1f
4e
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-154
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-154
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-662-7096
32 Fax: 215-615-3349
24
91
32 Fax: 215-615-3349
24
Email:
amy.clark@uphs.upenn.edu
12
amy.clark@uphs.upenn.edu
13
Education:
21 7 BS 14 (Biology) c
2a Haverford College, 1999.
21 7 MD 15 (Medicine) c
49 Milton S. Hershey Penn State College of Medicine, 2006.
21 9 MSCE 22 (Clinical Epidemiology) c
33 University of Pennsylvania, 2012.
c
3
3
3
3
8d
Permanent link21 7 BS 14 (Biology) c
2a Haverford College, 1999.
21 7 MD 15 (Medicine) c
49 Milton S. Hershey Penn State College of Medicine, 2006.
21 9 MSCE 22 (Clinical Epidemiology) c
33 University of Pennsylvania, 2012.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
cb I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.71
Description of Research Expertise
102 My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.e 29
23
10b R. Jaber Chehayeb; P. Coutifaris; F. White; J. Heintz; S. L. Jacob; J. Q. Zhang; O. M. Fayanju; E. S. Lebrow; N. Taunk; K. Lee; H. Knollman; I. Makhlin; A. Clark; R. Jankowitz; A. Nayak; S. Domchek; A. DeMichele; P. D. Shah cf : Factors associated with pCR and distant recurrence in patients with early-stage TNBC treated with KN522. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2025.
353 Paula R. Pohlmann, Hope S. Rugo, Christina Yau, Douglas Yee, A. Jo Chien, Nicole Williams, Anne M. Wallace, Judy C. Boughey, Christos Vaklavas, Mili Arora, Virginia Borges, Amy S. Clark, Coral Omene, Claudine Isaacs, Erica Stringer-Reasor, Rita Nanda, Carla Falkson, Kathy S. Albain, Nancy Chan, Evanthia Roussos Torres, Mariya Rozenblit, Jennifer Tseng, Satya Bommakanti, Chaitali Nangia, Lamorna Brown-Swigart, Gillian L. Hirst, Neel Pasricha, Crystal H. Kretzer, Jane Perlmutter, Alexander Borowsky, W. Fraser Symmans, Laura van ‘t Veer, Nola Hylton, Laura J. Esserman: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788 in the neoadjuvant setting: Results from the I-SPY2.2 trial. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2025.
1ff DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A.: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial 33 Nature Medicine Sep 2025.
1c1 Clark, A. S., Zhao, F., Klein, P., Montero, A. J., Falkson, C., Krill-Jackson, E., Rowland, K., Sardesai, S., Incorvati, J., Dillon, P., Wolff, A. C., Trauger, R., Heineman, T. C., Coffey, M. C., & Miller, K. D.: A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study 3b Clinical cancer research Jun 2025.
1d8 Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B.: Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. Breast Cancer Res Treat Jun 2025.
227 Garrido-Castro, C. A., Gorthi, A., Kim S.E., D'Ippolito, A., Nanda, R., Abdou, Y., Clark, A. S., Sacks, R. L., O'Connor, T. P., Sinclair, N., Lo, K.M.S., Desrosiers, J., Lin, N. U., Burstein, H. J., Mittendorf, E.A., Painter, C., Eaton, M. L., Barrett, C., Tayob, N., Tolaney, S.M. : Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer 2025 ASCO Annual Meeting May 2025.
1b6 Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD: BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer Clinical Cancer Research Apr 2025.
193 Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S.: FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications medicine Mar 2025 Notes: https://doi.org/10.1038/s43856-025-00791-0.
1cb Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B.: Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy 6b JACC. CardioOncology Feb 2025 Notes: https://doi.org/10.1016/j.jaccao.2025.01.012.
2c
7
1d
1f
Selected Publications
21d Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. df : I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC) 2 72 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 2025 Notes: Poster Presentation10b R. Jaber Chehayeb; P. Coutifaris; F. White; J. Heintz; S. L. Jacob; J. Q. Zhang; O. M. Fayanju; E. S. Lebrow; N. Taunk; K. Lee; H. Knollman; I. Makhlin; A. Clark; R. Jankowitz; A. Nayak; S. Domchek; A. DeMichele; P. D. Shah cf : Factors associated with pCR and distant recurrence in patients with early-stage TNBC treated with KN522. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2025.
353 Paula R. Pohlmann, Hope S. Rugo, Christina Yau, Douglas Yee, A. Jo Chien, Nicole Williams, Anne M. Wallace, Judy C. Boughey, Christos Vaklavas, Mili Arora, Virginia Borges, Amy S. Clark, Coral Omene, Claudine Isaacs, Erica Stringer-Reasor, Rita Nanda, Carla Falkson, Kathy S. Albain, Nancy Chan, Evanthia Roussos Torres, Mariya Rozenblit, Jennifer Tseng, Satya Bommakanti, Chaitali Nangia, Lamorna Brown-Swigart, Gillian L. Hirst, Neel Pasricha, Crystal H. Kretzer, Jane Perlmutter, Alexander Borowsky, W. Fraser Symmans, Laura van ‘t Veer, Nola Hylton, Laura J. Esserman: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788 in the neoadjuvant setting: Results from the I-SPY2.2 trial. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2025.
1ff DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A.: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial 33 Nature Medicine Sep 2025.
1c1 Clark, A. S., Zhao, F., Klein, P., Montero, A. J., Falkson, C., Krill-Jackson, E., Rowland, K., Sardesai, S., Incorvati, J., Dillon, P., Wolff, A. C., Trauger, R., Heineman, T. C., Coffey, M. C., & Miller, K. D.: A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study 3b Clinical cancer research Jun 2025.
1d8 Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B.: Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. Breast Cancer Res Treat Jun 2025.
227 Garrido-Castro, C. A., Gorthi, A., Kim S.E., D'Ippolito, A., Nanda, R., Abdou, Y., Clark, A. S., Sacks, R. L., O'Connor, T. P., Sinclair, N., Lo, K.M.S., Desrosiers, J., Lin, N. U., Burstein, H. J., Mittendorf, E.A., Painter, C., Eaton, M. L., Barrett, C., Tayob, N., Tolaney, S.M. : Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer 2025 ASCO Annual Meeting May 2025.
1b6 Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD: BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer Clinical Cancer Research Apr 2025.
193 Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S.: FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications medicine Mar 2025 Notes: https://doi.org/10.1038/s43856-025-00791-0.
1cb Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B.: Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy 6b JACC. CardioOncology Feb 2025 Notes: https://doi.org/10.1016/j.jaccao.2025.01.012.
2c